280 related articles for article (PubMed ID: 22020934)
1. Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1).
Chen CC; Hardy DB; Mendelson CR
J Biol Chem; 2011 Dec; 286(50):43091-102. PubMed ID: 22020934
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors.
Faivre EJ; Daniel AR; Hillard CJ; Lange CA
Mol Endocrinol; 2008 Apr; 22(4):823-37. PubMed ID: 18202149
[TBL] [Abstract][Full Text] [Related]
3. The requirement for p42/p44 MAPK activity in progesterone receptor-mediated gene regulation is target gene-specific.
Treviño LS; Bingman WE; Edwards DP; Nl W
Steroids; 2013 Jun; 78(6):542-7. PubMed ID: 23380370
[TBL] [Abstract][Full Text] [Related]
4. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators.
Faivre E; Skildum A; Pierson-Mullany L; Lange CA
Steroids; 2005; 70(5-7):418-26. PubMed ID: 15862825
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.
Wu W; Pew T; Zou M; Pang D; Conzen SD
J Biol Chem; 2005 Feb; 280(6):4117-24. PubMed ID: 15590693
[TBL] [Abstract][Full Text] [Related]
6. Mitogen-activated protein kinase phosphatase 1/dual specificity phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation.
Horsch K; de Wet H; Schuurmans MM; Allie-Reid F; Cato AC; Cunningham J; Burrin JM; Hough FS; Hulley PA
Mol Endocrinol; 2007 Dec; 21(12):2929-40. PubMed ID: 17761948
[TBL] [Abstract][Full Text] [Related]
7. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F; González-Navarrete I; Bragado R; Dalmases A; Menéndez S; Cortes-Sempere M; Suárez C; Oliva C; Servitja S; Rodriguez-Fanjul V; Sánchez-Pérez I; Campas C; Corominas JM; Tusquets I; Bellosillo B; Serrano S; Perona R; Rovira A; Albanell J
Clin Cancer Res; 2009 May; 15(10):3530-9. PubMed ID: 19417026
[TBL] [Abstract][Full Text] [Related]
8. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells.
Le Bihan S; Marsaud V; Mercier-Bodard C; Baulieu EE; Mader S; White JH; Renoir JM
Mol Endocrinol; 1998 Jul; 12(7):986-1001. PubMed ID: 9658403
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.
Knutson TP; Daniel AR; Fan D; Silverstein KA; Covington KR; Fuqua SA; Lange CA
Breast Cancer Res; 2012 Jun; 14(3):R95. PubMed ID: 22697792
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells.
Faivre EJ; Lange CA
Mol Cell Biol; 2007 Jan; 27(2):466-80. PubMed ID: 17074804
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells.
Davaadelger B; Murphy AR; Clare SE; Lee O; Khan SA; Kim JJ
Endocrinology; 2018 Oct; 159(10):3581-3595. PubMed ID: 30203004
[TBL] [Abstract][Full Text] [Related]
12. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
Labriola L; Salatino M; Proietti CJ; Pecci A; Coso OA; Kornblihtt AR; Charreau EH; Elizalde PV
Mol Cell Biol; 2003 Feb; 23(3):1095-111. PubMed ID: 12529413
[TBL] [Abstract][Full Text] [Related]
13. Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells.
Daniel AR; Lange CA
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14287-92. PubMed ID: 19706513
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
[TBL] [Abstract][Full Text] [Related]
15. TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone.
Gizard F; Robillard R; Gross B; Barbier O; Révillion F; Peyrat JP; Torpier G; Hum DW; Staels B
Mol Cell Biol; 2006 Oct; 26(20):7632-44. PubMed ID: 17015480
[TBL] [Abstract][Full Text] [Related]
16. The role of dual‑specificity phosphatase 1 and protein phosphatase 1 in β2‑adrenergic receptor‑mediated inhibition of extracellular signal regulated kinase 1/2 in triple negative breast cancer cell lines.
Tuglu MM; Bostanabad SY; Ozyon G; Dalkiliç B; Gurdal H
Mol Med Rep; 2018 Jan; 17(1):2033-2043. PubMed ID: 29257221
[TBL] [Abstract][Full Text] [Related]
17. Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER/PR target genes.
Diep CH; Ahrendt H; Lange CA
Steroids; 2016 Oct; 114():48-58. PubMed ID: 27641443
[TBL] [Abstract][Full Text] [Related]
18. Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
Hardy DB; Janowski BA; Chen CC; Mendelson CR
Mol Endocrinol; 2008 Aug; 22(8):1812-24. PubMed ID: 18483177
[TBL] [Abstract][Full Text] [Related]
19. Multimodal regulation of E2F1 gene expression by progestins.
Wade HE; Kobayashi S; Eaton ML; Jansen MS; Lobenhofer EK; Lupien M; Geistlinger TR; Zhu W; Nevins JR; Brown M; Otteson DC; McDonnell DP
Mol Cell Biol; 2010 Apr; 30(8):1866-77. PubMed ID: 20123965
[TBL] [Abstract][Full Text] [Related]
20. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
Wu J; Brandt S; Hyder SM
Mol Endocrinol; 2005 Feb; 19(2):312-26. PubMed ID: 15528272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
